Legend Biotech Corp
NASDAQ:LEGN

Watchlist Manager
Legend Biotech Corp Logo
Legend Biotech Corp
NASDAQ:LEGN
Watchlist
Price: 42.58 USD -0.26% Market Closed
Market Cap: 7.8B USD
Have any thoughts about
Legend Biotech Corp?
Write Note

Legend Biotech Corp
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Legend Biotech Corp
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Legend Biotech Corp
NASDAQ:LEGN
Cash from Operating Activities
-$393.3m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Legend Biotech Corp
Glance View

Market Cap
7.8B USD
Industry
Biotechnology

Legend Biotech Corp. is a pioneering biotechnology company that has made significant strides in the field of cell therapy, particularly with its innovative approaches to treating cancer. Founded in 2014 and based in Somerset, New Jersey, Legend is at the forefront of developing advanced therapies that harness the power of the immune system. At the heart of its mission is its flagship product, a revolutionary chimeric antigen receptor T-cell (CAR-T) therapy aimed at targeting and eliminating cancer cells. Following promising clinical results, the company has attracted attention from investors looking for high-growth opportunities in the ever-evolving biotech landscape. With strategic partnerships, including a noteworthy collaboration with Johnson & Johnson's Janssen division, Legend is set to leverage substantial resources towards the commercialization of its therapies. For potential investors, Legend Biotech represents both opportunity and risk, typical of the biotechnology sector. The company operates in a competitive market but has positioned itself with a promising pipeline and a robust intellectual property portfolio that supports its growth initiatives. Its focus on personalized medicine not only aligns with current healthcare trends but also offers the potential for high returns, especially as the demand for effective cancer treatments continues to rise. As Legend progresses through clinical trials and moves towards regulatory approvals, investors will be keenly watching its developments, as successful outcomes could significantly enhance its market position and drive its stock value upward.

LEGN Intrinsic Value
36.68 USD
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Legend Biotech Corp's Cash from Operating Activities?
Cash from Operating Activities
-393.3m USD

Based on the financial report for Dec 31, 2023, Legend Biotech Corp's Cash from Operating Activities amounts to -393.3m USD.

What is Legend Biotech Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-21%

Over the last year, the Cash from Operating Activities growth was -95%. The average annual Cash from Operating Activities growth rates for Legend Biotech Corp have been -21% over the past three years .

Back to Top